RT Journal Article
SR Electronic
T1 Multicenter Phase II Trial of First-line Docetaxel/Gemcitabine in Advanced Breast Cancer Pretreated with Adjuvant Anthracyclines
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1841
OP 1845
VO 29
IS 5
A1 VICI, PATRIZIA
A1 GIOTTA, FRANCESCO
A1 DI LAURO, LUIGI
A1 BRANDI, MARIO
A1 GEBBIA, VITTORIO
A1 FOGGI, PAOLO
A1 LORUSSO, VITO
A1 VITUCCI, CARLO
A1 SERGI, DOMENICO
A1 FATTORUSO, SILVIA ILEANA
A1 GIANNARELLI, DIANA
A1 VIOLA, GIUDITTA
A1 CORSETTI, SERENA
A1 COLUCCI, GIUSEPPE
A1 LOPEZ, MASSIMO
YR 2009
UL http://ar.iiarjournals.org/content/29/5/1841.abstract
AB The aim of this study was to evaluate activity and tolerability of docetaxel-gemcitabine combination as first-line treatment in patients with metastatic breast cancer previously treated with adjuvant anthracyclines. Patients and Methods: Sixty-eight women received gemcitabine 1,000 mg/m2 as 30-minute infusion on days 1 and 8, and docetaxel 80 mg/m2 as 1-hour infusion on day 8, with cycles repeated every 3 weeks. Results: Objective responses were observed in 32 out of 68 evaluable patients (45%; 95% confidence interval, 35.2-58.8%). Responses were 44%, 42%, 49% in soft tissue, bone and visceral lesions, respectively, 50% /52% in HER2-positive/-negative tumors, and 50% in both ER- positive/-negative tumors. Median time to progression and overall survival were 6 and 16 months, respectively. Treatment was usually well tolerated, with grade 3-4 neutropenia in 32% - 7% of the patients, and neutropenic fever, grade 3 vomiting, mucositis and peripheral neurotoxicity in 3% of the patients. Conclusion: Gemcitabine-docetaxel combination is effective and well tolerated as first-line treatment in advanced breast cancer previously treated with adjuvant anthracyclines.